Clearside Biomedical Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon. I'm Serge Belanger, one of the senior healthcare analysts at Needham. I want to welcome you to our 22nd Annual Healthcare Conference.
For our next session, we're going to be talking with Clearside Biomedical. And we have the company's CEO, George Lasezkay, with us today, who's going to give us an overview and talk about the recently unveiled Phase 2b trial design called -- from the ODYSSEY trial. So I'll hand it over to George, and you can give us the overview.
All right. Thanks, Serge. Appreciate being invited to be part of the Needham Conference, and it's our pleasure and privilege to be here.
And so let me just take you through just some very brief slides about the company and then we'll get into what we recently announced yesterday, which was our plans and our design for our Phase 2b trial with our tyrosine kinase inhibitor, axitinib, in Wet AMD patients.
During this presentation, I will be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
